27 Jun. 2023
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing 
21 Jun. 2023
Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases
16 Jun. 2023
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs)
17 Apr. 2023
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development
04 Apr. 2023
Foresee announced the Primary Endpoint Results of FP-025 in an Allergic Asthma Phase 2a Trial
31 May. 2022
